Propanc Biopharma

Company snapshot

Propanc Biopharma is a biotech organization headquartered in CAMBERWELL, VICTORIA, C3, USA. It trades on NYSE under ticker PPCB. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 3 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 3 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Propanc Biopharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Propanc Biopharma.

1. Sep 23, 2025 Patent grant

   Proenzyme composition

2. Jul 5, 2022 Patent grant

   Cancer treatment

3. Jul 16, 2019 Patent grant

   Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

View all clinical trial activity →

• What is Propanc Biopharma?

  Propanc Biopharma is a biotech organization headquartered in CAMBERWELL, VICTORIA, C3, USA. It trades on NYSE under ticker PPCB. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 3 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPT

• Is Propanc Biopharma publicly traded?

  Yes. Propanc Biopharma is listed with ticker PPCB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Propanc Biopharma develop or market?

  No drug profiles are currently linked to Propanc Biopharma. Pipeline programs may still list investigational assets.

• What are the latest developments for Propanc Biopharma?

  In the last 12 months our linked public records show 0 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Propanc Biopharma focus on?

  No specific therapeutic focus areas are currently identified for Propanc Biopharma in our database.